NASDAQ$ARVN

Arvinas Inc. · Q3 2025 earnings

Q3 2025 earnings · · Before market open · Investor relations

Briefing

Arvinas reported a Q3 2025 net loss with significantly reduced R&D and G&A expenses and lower collaboration revenue due to concluded agreements.

Arvinas posted a net loss of $35.1 million for Q3 2025, reflecting decreased collaboration revenue and reduced operating expenses as the company transitions development responsibilities to partners.

  • Q3 2025 revenue was $41.9 million, primarily from the Pfizer collaboration.
  • GAAP R&D expenses dropped to $64.7 million, down from $86.9 million in Q3 2024.
  • GAAP G&A expenses decreased sharply to $21.0 million from $75.8 million year-over-year.
  • Arvinas ended the quarter with $787.6 million in cash, cash equivalents, and marketable securities.

Headline financials

Total Revenue

$41.9M

Previous: $102M-59.1%
EPS (adj)

-$0.48

Previous: -$0.68+29.4%
R&D Expenses

$64.7M

Previous: $86.9M-25.5%
G&A Expenses

$21M

Previous: $75.8M-72.3%
Capital Expenditures

-$1.7M

Previous: -$1.5M-13.3%
Net Income

-$35.1M

Previous: -$49.2M+28.7%
Operating Income

-$43.8M

Previous: -$60.3M+27.4%

Revenue & EPS history

Arvinas · Revenue · Quarterly

$41.9M

Q3 2025-59.1%vs Q3 2024
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Revenue by segment

Arvinas · $30.3M total across 1 segment · Q3 2022

  • Collaboration Revenue
    $30.3M+225.8%

Forward guidance

Arvinas expects its current cash position to fund operations into the second half of 2028 while it advances early-stage clinical and preclinical assets.

Tailwinds

  • Strong cash position of $787.6 million to support pipeline development.
  • Positive Phase 1 clinical data for ARV-102 in Parkinson’s disease patients.
  • First preclinical data shared for ARV-027 showing disease-modifying potential in SBMA.
  • ARV-806 demonstrated high potency and tumor regression in KRAS G12D models.
  • FDA accepted NDA for vepdegestrant, with PDUFA date set for June 5, 2026.

Headwinds

  • Q3 revenue fell sharply from prior year due to concluded Novartis and Bayer collaborations.
  • ARV-393 Phase 1 trial has not yet reached effective exposure levels.
  • Decreased cash from operations and stock repurchases reduced liquidity.
  • Significant net loss of $35.1 million in Q3 despite cost cuts.
  • Dependence on third-party commercialization plans for vepdegestrant may delay market entry.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-2.4%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-0.6%

Avg return

30 days after

30%

9 / 30 earnings

Positive

+11.8%

Q1 2019

Best reaction

-24.8%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.4%-10.2%
Q4 2025+5.2%+4.7%-7.4%
Q3 2025+0.5%+17.3%+34.1%
Q1 2025-24.8%-27.8%-25.2%
Q4 2024-6.8%-3.5%-54.9%
Q3 2024-3.9%-2.5%-2.8%
Q2 2024-1.0%-7.0%-6.3%
Q1 2024+0.3%-2.5%-14.1%
Q4 2023-5.8%-3.1%-15.4%
Q3 2023-2.5%-11.5%+93.1%
Q2 2023+2.1%+6.8%+12.8%
Q1 2023+4.9%+3.0%-1.2%
Q4 2022-7.0%-10.8%-23.0%
Q3 2022-4.0%+17.9%-12.5%
Q2 2022+3.8%+4.5%-19.3%
Q1 2022-16.4%-22.6%-19.0%
Q4 2021-2.6%-4.4%-5.4%
Q3 2021+4.9%+1.2%-18.8%
Q2 2021-4.3%-8.9%-13.4%
Q1 2021-4.0%-9.1%-1.7%
Q4 2020-1.0%-8.0%-15.6%
Q3 2020-3.6%+4.3%+18.6%
Q2 2020-5.0%-11.1%-23.0%
Q1 2020-0.9%-6.0%-17.7%
Q4 2019-3.2%-1.8%+14.2%
Q3 2019+3.3%+17.6%+79.4%
Q2 2019-4.6%-0.2%-1.5%
Q1 2019+11.8%+11.1%+0.8%
Q4 2018-3.0%-6.9%+42.9%
Q3 2018-0.1%+7.3%-13.6%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro